Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

572 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations.
Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y. Ninomiya K, et al. Among authors: yamaguchi o. JTO Clin Res Rep. 2020 Oct 12;2(1):100107. doi: 10.1016/j.jtocrr.2020.100107. eCollection 2021 Jan. JTO Clin Res Rep. 2020. PMID: 34589972 Free PMC article. Review.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Saito H, et al. Among authors: yamaguchi o. Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8. Lancet Oncol. 2019. PMID: 30975627 Clinical Trial.
A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
Minegishi Y, Yamaguchi O, Sugawara S, Kuyama S, Watanabe S, Usui K, Mori M, Hataji O, Nukiwa T, Morita S, Kobayashi K, Gemma A. Minegishi Y, et al. Among authors: yamaguchi o. BMC Cancer. 2021 Mar 1;21(1):208. doi: 10.1186/s12885-021-07861-1. BMC Cancer. 2021. PMID: 33648453 Free PMC article.
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Haratani K, Teraoka S, Tokito T, Murakami S, Tamiya A, Itoh S, Yokouchi H, Watanabe S, Yamaguchi O, Tomii K, Yamamoto N. Fujimoto D, et al. Among authors: yamaguchi o. Eur J Cancer. 2021 Jun;150:63-72. doi: 10.1016/j.ejca.2021.03.016. Epub 2021 Apr 20. Eur J Cancer. 2021. PMID: 33892408
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Kawashima Y, et al. Among authors: yamaguchi o. Lancet Respir Med. 2022 Jan;10(1):72-82. doi: 10.1016/S2213-2600(21)00166-1. Epub 2021 Aug 26. Lancet Respir Med. 2022. PMID: 34454653 Clinical Trial.
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer.
Fujimoto D, Miura S, Tomii K, Sumikawa H, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Kijima T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Tokito T, Murakami S, Tamiya A, Yokouchi H, Watanabe S, Yamaguchi O, Morinaga R, Jodai T, Ito K, Shiraishi Y, Kogure Y, Shibaki R, Yamamoto N. Fujimoto D, et al. Among authors: yamaguchi o. Sci Rep. 2023 Mar 6;13(1):3698. doi: 10.1038/s41598-023-30676-y. Sci Rep. 2023. PMID: 36878936 Free PMC article.
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
Nakamura A, Yamaguchi O, Mori K, Miura K, Tamiya M, Oba T, Yanagitani N, Mizutani H, Ninomiya T, Kajiwara T, Ito K, Miyanaga A, Arai D, Kodama H, Kobayashi K, Kaira K. Nakamura A, et al. Among authors: yamaguchi o. Eur J Cancer. 2023 May;184:62-72. doi: 10.1016/j.ejca.2023.01.025. Epub 2023 Feb 11. Eur J Cancer. 2023. PMID: 36905770
572 results